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Gaucher’s disease is a hereditary deficiency of the enzyme b-glucocerebrosidase (GCase) that is most
commonly treated by enzyme replacement therapy. In this issue of Chemistry & Biology, Tan and colleagues
search for alternative ways to rehabilitate mutant GCase by understanding how it interacts with the proteo-
stasis network.In each crowded subcellular compart-
ment, misfolded proteins must be
removed to limit the damage caused
by nonnative interactions. The system
responsible for identifying misfolded
proteins is an integrated collection of
molecular chaperones, cochaperones,
folding enzymes, proteases, and the like
comprising the proteostasis network
(Powers et al., 2009). The activity of this
network, regulated by compartment-spe-
cific stress-responsive signaling, is crucial
to survival because accumulation of mis-
folded proteins is often proteotoxic. How-
ever, a hypervigilant proteostasis network
leads to the opposite problem: loss-of-
function diseases. In these disorders,
such as cystic fibrosis, the disease-asso-
ciated protein is incorrectly classified as
‘‘unfoldable,’’ and it is removed from the
cell by targeted proteolysis. One way to
treat loss-of-function diseases might be
to dial back the sensitivity of the proteo-
stasis network, allowing a folding compro-
mised, but folding capable, protein to
pass the quality control checks (Powers
et al., 2009). The questions are—what
components of the network have this
activity and which are the best drug tar-
gets? In this issue of Chemistry & Biology,
Tan et al. (2014) provide proof-of-prin-
ciple that this approach is possible for
Gaucher’s disease.
By way of introduction, b-glucocerebro-
sidase (GCase) is a lysosomal enzyme
responsible for the conversion of glucosyl-
ceramide into glucose and ceramide. Loss
ofGCaseactivity, due to inactivatingmuta-
tions and/or overzealous quality control
(degradation), leads to a buildup of gluco-
cerebrosides and the degenerative lyso-
somal storage disorder, Gaucher’s dis-
ease (Mignot et al., 2013). The GCase
enzyme is normally glycosylated andfolded in the endoplasmic reticulum (ER)
and is subsequently trafficked through
the Golgi to the lysosome. Chaperone
proteins, including the Ca2+ activated lec-
tins, calnexin and calreticulin, are known
to assist in the folding process (Figure 1).
However, GCase mutations that slow
folding appear to be interpreted as a
‘‘danger signal’’ by the proteostasis
network, triggering ER-associated degra-
dation (ERAD). In this scenario, mutant
GCase is retrotranslocated to the cyto-
plasm, ubiquitinated, and degraded by
theproteasome. Interestingly,mostGCase
mutants would have sufficient enzymatic
activity if they could be folded and traf-
ficked to the lysosome. The apparently
overactive proteostasis network reduces
lysosomal GCase activity below critical
levels for efficient substrate turnover.
Gaucher’s disease is currently treated
using enzyme replacement therapy (ERT),
which involves biweekly intravenous
administration of a recombinant wild-type
GCase (Bennett andMohan, 2013). Unfor-
tunately, ERT does not improve the neuro-
logical defects associated with Gaucher’s
disease, because the recombinant protein
cannot cross the blood-brain barrier.
Other treatment strategies, such as sub-
strate reduction therapy or the useof phar-
macological chaperones, continue to be
explored (Boyd and Valenzano, 2014).
Although promising, these approaches
are expected to be Gaucher’s disease
specific. Another approach would be
to alter the proteostasis network itself.
This approach has the potential to treat a
broader rangeof loss-of-functiondiseases
if the right network ‘‘hub’’ could be identi-
fied (Powers et al., 2009).
Toward this end, Tan et al. (2014) set out
to identify the proteins that interact with
wild-type (WT) GCase. Using immunopre-Chemistry & Biology 21, August 14, 2014cipitation and mass spectrometry, they
were able to identify known interactors,
such as calnexin/calreticulin. They also
identified a handful of novel interactors,
and, from this list, onenetwork component
stood out: ERdj3 (also known as
DnaJB11). ERdj3 is an ER resident Hsp40
cochaperone whose conventional role is
to deliver client proteins to the heat shock
protein 70 (Hsp70/BiP) of theER (Shenand
Hendershot, 2005). GCase was not previ-
ously known to be an ERdj3 client. A clas-
sical pulldown experiment confirmed that
ERdj3 indeed binds toWT and to a greater
extent to mutant (L444P) GCase, suggest-
ing that it might be a triage factor for this
protein. Consistent with this idea, knock-
down of ERdj3 slowed degradation of
L444P GCase and resulted in an increase
in activity up to 20% of WT lysosomal
GCase activity. This extent of increase in
activity would be expected to significantly
reduce disease symptoms, because sub-
strate buildup is known to occur when
enzyme activity drops below a threshold
of 15%. Importantly, WT GCase was not
affectedbyERdj3 knockdown, suggesting
that ERdj3 is only a critical factor for recog-
nizing unstable enzymes.
Given ERdj30s known roles in the
Hsp70/BiP system (Shen and Hender-
shot, 2005), it seemed plausible that it
was acting through that pathway. How-
ever, previous work had shown no role
for BiP in GCase maturation and, indeed,
Tan et al. (2014) showed that knockdown
of another major Hsp70/BiP cochaper-
one, HYOU1, had no observable effect.
Rather, the mass spectrometry study
suggested that the calnexin/calreticulin
system and ERdj3 might compete for
folding compromised GCase mutants
(Figure 1). Calnexin and calreticulin are
Ca2+ dependent chaperones whoseª2014 Elsevier Ltd All rights reserved 919
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Figure 1. Mutant GCase Is Prematurely Triaged by ERdj3 within the Proteostasis Network
Lysosomal GCase is normally folded and processed in the ER-Golgi with the help of the chaperone pro-
teins calnexin and calreticulin. Tan et al. (2014) use unbiased approaches to show that GCase mutants
associated with Gaucher’s disease preferentially interact with a different chaperone, ERdj3. This inter-
action couples the mutant enzyme to the ERAD degradation pathway, leading to loss-of-function. The
partitioning of GCase between calnexin/calreticulin and ERdj3 seems to regulate GCase quality control,
suggesting ways of treating the disease.
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with diltiazem, an ER Ca2+ efflux inhibitor.
Thus, the authors predicted that diltiazem
treatment might be synergistic with siRNA
knockdown of ERdj3, and, indeed, they
observed that L444P GCase activity was
increased to 50% of WT after a 7-day
treatment.
This work provides important insight
into the mechanisms of GCase quality
control, and it suggests that mutant
GCase stands at a crucial juncture; with
one path leading to proper folding and
trafficking by the calnexin/calreticulin ma-
chinery and another leading to prolonged
interactions with ERdj3 and eventual
ERAD (Figure 1). Perhaps more impor-920 Chemistry & Biology 21, August 14, 2014tantly, this work illustrates a path toward
the identification of potential drug targets
within the proteostasis network. Specif-
ically, this work suggests that inhibitors
of the interaction between ERdj3 and
GCase might allow mutant enzyme
to escape premature degradation. We
believe that it would have been difficult
or impossible to predict this target in
the absence of the unbiased screen.
Whether ERdj3 plays a similar role in other
ER-associated loss-of-function disorders
remains to be tested, and,more generally,
it isn’t yet clear how many clients are
acted upon by ERdj3.
A growing number of diseases have
been linked to imbalances in the proteo-ª2014 Elsevier Ltd All rights reservedstasis network. In neurodegenerative dis-
orders, insufficient quality control seems
to allow accumulation of misfolded pro-
teins (Gestwicki and Garza, 2012), while
in cancer, the aberrant decision to retain
oncogenes seems to contribute to patho-
biology (Miyata et al., 2013). Despite the
central importance of this system, only
a handful of drug targets within the pro-
teostasis network have been validated,
namely Hsp90 and the 26S proteasome.
In part, progress has been limited by
a relatively poor understanding of how
triage decisions are made by other key
‘‘hub’’ proteins. In this work, Tan et al.
(2014) uncover a detailed picture of how
GCase is handled by the proteostasis
network, revealing an unexpected drug
target and suggesting a combination
strategy for treatment. Patterned after
this work, exciting new targets within the
proteostasis network are expected to
emerge for other disorders.REFERENCES
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